West Pharamaceuticals has created 330 jobs as as part of the expansion of its manufacturing site at Damastown in Dublin.
The company today announced the opening of the new building, which is a 165,000 square foot expansion.
It now employs over 1,400 people in Ireland across its Dublin and Waterford sites.
West makes solutions and delivery systems for injectable medicines, including vials, seals, prefillable syringes, and self injection devices.
This new facility is set up to support high-volume injectable therapies, including for diabetes and obesity.
"West is honoured to continue supporting our customers in providing reliable, high-quality drug delivery solutions and security of supply," said Aileen Ruff-Patry, President of Contract Manufacturing.
"This expansion increases our global capacity to support drug handling for high-volume injectable therapies, including next-generation GLP-1 treatments," she said.
"This reinforces West's role as a critical partner in helping to secure patient access to these essential medicines," she added.
Michael Lohan, CEO of IDA Ireland, said this significant investment by West demonstrates the strength of Ireland’s value proposition as a location for innovation and large scale, high-value manufacturing projects, supported by a skilled workforce and collaborative ecosystem.
West said that as demand for complex injectable drug delivery systems continues to grow, access to integrated development and commercialization services to support these products becomes increasingly critical.
The Damastown expansion is expected to enhance the company's contract capabilities beyond its component molding, device assembly, and packaging to now include advanced automation and expanded drug-handling capabilities at commercial scale.
The work at this site is part of West Vantage™, the company’s comprehensive contract services business.
